PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsidiopathic pulmonary fibrosis
MeSH D054990 - idiopathic pulmonary fibrosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D011658:Pulmonary fibrosis
17 Companies
1 Drug
$
Success rate
D054990: 
Idiopathic pulmonary fibrosis
4 Companies
3 Drugs
$
Success rate
D000080203:Hamman-rich syndrome
0 Companies
0 Drugs
Success rate
D054988:Idiopathic interstitial pneumonias
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
AxunioPirfenidone Pirfenidone axunio (previously Pirfenidone AET)  2022-06-20   
Boehringer IngelheimNintedanib, Nintedanib esylate Ofev  2015-01-14   
Nintedanib Vargatef  2014-11-21   
RochePirfenidone Esbriet  2011-02-27 $749.525 M Y2022 
ViatrisPirfenidone Pirfenidone Viatris  2023-01-10   
Clinical Trials
Historical Success Rate
Phase 1
63%
17/27
Phase 2
35%
16/46
Phase 3
27%
10/37
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Boehringer Ingelheim
Nintedanib,
Nintedanib esylate,
Aspartame,
Bevifimod,
Xenon xe 127,
Chp
Roche
Pirfenidone,
Ademetionine,
Sodium chloride,
Evidence
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use